George Centre for Healthcare Innovation, University of Oxford, Richard Doll Building, Old Road Campus, Oxford, UK.
Eur Heart J. 2012 Jul;33(13):1571-81. doi: 10.1093/eurheartj/ehs005. Epub 2012 Feb 3.
The effect of statin treatment on ventricular arrhythmic complications is uncertain. We sought to test whether statins reduce the risk of ventricular tachyarrhythmia, cardiac arrest, and sudden cardiac death.
We searched MEDLINE, EMBASE, and CENTRAL up to October 2010. Randomized controlled trials comparing statin with no statin or comparing intensive vs. standard dose statin, with more than 100 participants and at least 6-month follow-up were considered for inclusion and relevant unpublished data obtained from the investigators. Twenty-nine trials of statin vs. control (113 568 participants) were included in the main analyses. In these trials, statin therapy did not significantly reduce the risk of ventricular tachyarrhythmia [212 vs. 209; odds ratio (OR) = 1.02, 95% confidence interval (CI) 0.84-1.25, P = 0.87] or of cardiac arrest (82 vs. 78; OR = 1.05, 95% CI 0.76-1.45, P = 0.84), but was associated with a significant 10% reduction in sudden cardiac death (1131 vs. 1252; OR = 0.90; 95% CI 0.82-0.97, P = 0.01). This compared with a 22% reduction in the risk of other 'non-sudden' (mostly atherosclerotic) cardiac deaths (1235 vs. 1553; OR = 0.78, 95% CI 0.71-0.87, P < 0.001). Results were not materially altered by inclusion of eight trials (involving 41 452 participants) of intensive vs. standard dose statin regimens.
Statins have a modest beneficial effect on sudden cardiac death. However, previous suggestions of a substantial protective effect on ventricular arrhythmic events could not be supported.
他汀类药物治疗对室性心律失常并发症的影响尚不确定。我们旨在检验他汀类药物是否能降低室性心动过速、心脏骤停和心源性猝死的风险。
我们检索了 MEDLINE、EMBASE 和 CENTRAL 数据库,检索截至 2010 年 10 月。我们纳入了比较他汀类药物与非他汀类药物或比较强化剂量他汀类药物与标准剂量他汀类药物的随机对照试验,这些试验的纳入对象至少为 100 例且随访时间至少 6 个月,同时还获取了研究者未发表的数据。共有 29 项他汀类药物与对照组(共 113568 例患者)的对比试验被纳入主要分析。这些试验中,他汀类药物治疗并未显著降低室性心律失常(212 例 vs. 209 例;比值比 [OR] = 1.02,95%置信区间 [CI] 0.84-1.25,P = 0.87)或心脏骤停(82 例 vs. 78 例;OR = 1.05,95% CI 0.76-1.45,P = 0.84)的风险,但与心源性猝死风险显著降低 10%相关(1131 例 vs. 1252 例;OR = 0.90;95% CI 0.82-0.97,P = 0.01)。相比之下,其他“非突发性”(主要为动脉粥样硬化性)心脏死亡的风险降低了 22%(1235 例 vs. 1553 例;OR = 0.78,95% CI 0.71-0.87,P < 0.001)。纳入 8 项比较强化剂量他汀类药物与标准剂量他汀类药物的试验(共 41452 例患者)后,结果并没有明显改变。
他汀类药物对心源性猝死有适度的有益作用。然而,先前关于他汀类药物对室性心律失常事件有实质性保护作用的说法并未得到证实。